US Broker Ratings

Amgen Inc. (AMGN) Stock Analysis: Exploring a Robust Revenue Growth and Strong ROE in the Competitive Biopharma Landscape

Amgen Inc. (NASDAQ: AMGN), a stalwart in the healthcare sector, continues to hold a formidable position within the drug manufacturing industry. With a market capitalization of $175.6 billion, this biopharmaceutical..

HealthEquity, Inc. (HQY) Stock Analysis: Exploring a 27.66% Potential Upside for Investors

HealthEquity, Inc. (NASDAQ: HQY) is garnering attention in the investor community with a strong potential upside of 27.66%, according to the latest analyst ratings. As a leader in the healthcare..

Boston Scientific Corporation (BSX) Stock Analysis: A Promising 28% Upside Potential for Investors

Boston Scientific Corporation (NYSE: BSX) is a prominent player in the global healthcare landscape, specifically within the medical devices industry. With a robust market capitalization of $144.75 billion, the company..

Align Technology, Inc. (ALGN) Stock Analysis: Navigating Growth Potential with a 4.44% Upside

Align Technology, Inc. (NASDAQ: ALGN) has long been a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. Best known for its revolutionary Invisalign clear..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Unveiling a 7.47% Upside with Strategic Positioning in Healthcare

Bio-Rad Laboratories, Inc. (NYSE: BIO) stands as a prominent player in the healthcare sector, focusing on developing, manufacturing, and distributing life science research and clinical diagnostic products. Headquartered in Hercules,..

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unveiling a 22.96% Potential Upside in the Biotech Sector

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stands as a prominent figure in the biotechnology industry, with a market capitalization of over $52 billion. Based in Cambridge, Massachusetts, Alnylam is a pioneer..

Vertex Pharmaceuticals (VRTX) Stock Analysis: High Potential Upside and Robust Growth Metrics Attract Investor Attention

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a major player in the biotechnology sector, continues to capture the interest of investors with its robust growth metrics and promising pipeline. Valued at approximately..

Zimmer Biomet Holdings (ZBH): Growth Potential in the Medical Device Sector Amidst Analyst Consensus

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) stands as a significant player in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $18.4 billion, this Warsaw,..

Waters Corporation (WAT) Stock Analysis: A Healthcare Giant with 3.34% Potential Upside

Investors with a keen interest in the healthcare sector may find Waters Corporation (NYSE: WAT) an intriguing prospect. Headquartered in Milford, Massachusetts, Waters Corporation operates in the diagnostics and research..

Sanofi (SNY) Stock Analysis: Unlocking a 19.69% Potential Upside with Strong Buy Ratings

Sanofi (SNY), a French healthcare giant, is attracting attention from investors thanks to its robust portfolio in drug manufacturing and impressive analyst ratings. With a market capitalization of $118.79 billion,..

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Robust 32% Potential Upside Highlights Growth Prospects

Investors seeking opportunities in the healthcare sector should turn their attention to Neurocrine Biosciences, Inc. (NBIX), a prominent player in the specialty and generic drug manufacturing industry. With a market..

The Ensign Group, Inc. (ENSG) Stock Analysis: Exploring a 19.74% Upside Potential in the Healthcare Sector

The Ensign Group, Inc. (NASDAQ: ENSG) stands as a formidable entity within the healthcare sector, specifically in the medical care facilities industry. With a market capitalization of $10.07 billion, this..

Encompass Health Corporation (EHC) Stock Analysis: A 36% Upside Potential with Strong Buy Ratings

Encompass Health Corporation (NYSE: EHC) is making waves in the healthcare sector, presenting an intriguing investment opportunity with a compelling 36.34% potential upside, according to current analyst ratings. With all..

Alcon Inc. (ALC) Stock Analysis: Is a 14.57% Upside Within Reach for This Healthcare Giant?

Alcon Inc. (ALC), a prominent player in the healthcare sector, is capturing the interest of investors with the potential for a substantial upside of 14.57%. As a Swiss-based company specializing..

Haleon plc (HLN) Stock Analysis: Exploring a 19.3% Potential Upside in the Healthcare Sector

Haleon plc (HLN), a prominent player in the healthcare sector, has been drawing attention from investors with its diverse portfolio of consumer healthcare products. Headquartered in Weybridge, United Kingdom, Haleon..

Danaher Corporation (DHR) Stock Analysis: Healthcare Giant’s 9.51% Upside and Strong Buy Consensus

Danaher Corporation (NYSE: DHR) stands as a formidable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $170.69 billion, the company is..

BioNTech SE (BNTX) Stock Analysis: Exploring a 39.63% Potential Upside in the Biotechnology Sector

BioNTech SE (BNTX), a prominent player in the biotechnology sector, has captured investor attention with its innovative strides in immunotherapy and a promising potential upside of 39.63%. As the company..

Astrazeneca PLC (AZN)

⚠️ No article content returned.

..

DexCom, Inc. (DXCM) Investor Outlook: 26.63% Potential Upside and Strong Buy Ratings

DexCom, Inc. (DXCM), a frontrunner in the healthcare sector specializing in medical devices, is gaining attention among investors with its robust growth trajectory and significant market presence. With a market..

Genmab A/S (GMAB) Stock Analysis: Unpacking the 10.37% Upside Potential for Biotech Investors

As one of the standout players in the biotechnology sector, Genmab A/S (GMAB) continues to capture the attention of investors with its promising product pipeline and strategic collaborations. With a..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds